GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » ROA %

Oncodesign Precision Medicine (XPAR:ALOPM) ROA % : -99.47% (As of Jun. 2022)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Oncodesign Precision Medicine's annualized Net Income for the quarter that ended in Jun. 2022 was €-6.51 Mil. Oncodesign Precision Medicine's average Total Assets over the quarter that ended in Jun. 2022 was €6.55 Mil. Therefore, Oncodesign Precision Medicine's annualized ROA % for the quarter that ended in Jun. 2022 was -99.47%.

The historical rank and industry rank for Oncodesign Precision Medicine's ROA % or its related term are showing as below:

XPAR:ALOPM's ROA % is not ranked *
in the Biotechnology industry.
Industry Median: -35.515
* Ranked among companies with meaningful ROA % only.

Oncodesign Precision Medicine ROA % Historical Data

The historical data trend for Oncodesign Precision Medicine's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine ROA % Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21
ROA %
-1.24 -28.33

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22
ROA % - - -99.47

Competitive Comparison of Oncodesign Precision Medicine's ROA %

For the Biotechnology subindustry, Oncodesign Precision Medicine's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncodesign Precision Medicine's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's ROA % distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's ROA % falls into.



Oncodesign Precision Medicine ROA % Calculation

Oncodesign Precision Medicine's annualized ROA % for the fiscal year that ended in Dec. 2021 is calculated as:

ROA %=Net Income (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=-2.944/( (12.409+8.372)/ 2 )
=-2.944/10.3905
=-28.33 %

Oncodesign Precision Medicine's annualized ROA % for the quarter that ended in Jun. 2022 is calculated as:

ROA %=Net Income (Q: Jun. 2022 )/( (Total Assets (Q: Dec. 2021 )+Total Assets (Q: Jun. 2022 ))/ count )
=-6.512/( (8.372+4.722)/ 2 )
=-6.512/6.547
=-99.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Jun. 2022) net income data. ROA % is displayed in the 30-year financial page.


Oncodesign Precision Medicine  (XPAR:ALOPM) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2022 )
=Net Income/Total Assets
=-6.512/6.547
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-6.512 / 0.878)*(0.878 / 6.547)
=Net Margin %*Asset Turnover
=-741.69 %*0.1341
=-99.47 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2022) net income data. The Revenue data used here is two times the semi-annual (Jun. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Oncodesign Precision Medicine ROA % Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncodesign Precision Medicine (XPAR:ALOPM) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (XPAR:ALOPM) Headlines

No Headlines